白念珠菌生物膜体内外模型研究进展

中国真菌学杂志　 2012, Vol. 7 　Issue (6): 380-384.

综述上一篇

白念珠菌生物膜体内外模型研究进展

邵菁, 汪长中, 汪天明, 程惠娟

安徽中医学院微生物学与免疫学教研室,合肥 230038

收稿日期:2012-09-15 出版日期:2012-12-28 发布日期:2012-12-28
通讯作者: 汪长中 E-mail:ahwcz63@sina.com
作者简介:邵菁,男 (汉族),博士,讲师.E-mail:ustcsj@126.com
基金资助:
国家自然科学基金 (81073127),安徽省自然科学基金 (090413092),安徽省高校省级自然科学研究重点项目 (KJ2010A220)

Advances of Candida albicans biofilm construction in vitro and in vivo

SHAO Jing, WANG Chang-zhong, WANG Tian-ming, CHENG Hui-juan

Department of Microbiology and Immunology,Anhui University of Traditional Chinese Medicine,Hefei 230038,China

Received:2012-09-15 Online:2012-12-28 Published:2012-12-28

摘要/Abstract

摘要：

白念珠菌引起的慢性难治性感染与其形成的生物膜密切相关,生物膜的诸多生物学特征明显不同于游离菌。合适的生物膜模型的构建对于研究白念珠菌生物膜的形成机制以及药物干预至关重要。该文结合作者自身的研究,对目前国内外关于白念珠菌生物膜体外、体内多种模型的构建方法作一综述。

关键词: 白念珠菌, 生物膜, 体内模型, 体外模型

Abstract:

The chronic and refractory candidal infections caused by Candida albicans have close relations with its biofilms formation. Many biological characteristics of biofilm are different from those of planktonic counterparts. Proper constructions of biofilm model are critical to the researches of the mechanism of biofilm formation and medicinal intervention. In this paper, the authors make a comprehensive review of in vitro and in vivo biofilm constructions of Candida albicans at home and abroad according to their studies.

Key words: Candida albicans, biofilm, in vivo model, in vitro model

中图分类号:

R 379.4

邵菁, 汪长中, 汪天明, 程惠娟. 白念珠菌生物膜体内外模型研究进展[J]. 中国真菌学杂志, 2012, 7(6): 380-384.

SHAO Jing, WANG Chang-zhong, WANG Tian-ming, CHENG Hui-juan. Advances of Candida albicans biofilm construction in vitro and in vivo[J]. Chinese Journal of Mycology, 2012, 7(6): 380-384.

参考文献

[1] Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care
[J]. BMC Infect Dis,2006,6:21.

[2] Tobudic S,Kratzer C,Lassnigg A,et al. Antifungal susceptibility of Candida albicans in biofilms
[J]. Mycoses,2012, 55(3): 199-204.

[3] Davies D. Understanding biofilm resistance to antibacterial agents
[J]. Nat Rev Drug Discov, 2003, 2(2): 114-122.

[4] Ramage G, Vande Walle K, Wickes BL, et al.Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms
[J]. Antimicrob Agents Chemother,2001, 45(9): 2475-2479.

[5] Nweze EI, Ghannoum A, Chandra J, et al. Development of a 96-well catheter-based microdilution method to test antifungal susceptibility of Candida biofilms
[J]. J Antimicrob Chemother, 2012, 67(1): 149-153.

[6] Lafleur MD, Lucumi E, Napper AD, et al. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms
[J]. J Antimicrob Chemother,2011, 66(4): 820-826.

[7] 赵今,李继遥,朱昞,等. 口腔多菌种生物膜对防龋中药敏感性的实验研究
[J].华西口腔医学杂志,2006,24(6):546-550.

[8] Ceri H, Olson ME, Stremick C, et al. The Calgary Biofilm Device: Measurement of antimicrobial sensitivity of bacterial biofilms
[J]. J Clin Microbiol, 1999, 37: 1771-1776.

[9] Harrison JJ, Turner RJ, Ceri H. High-throughput metal susceptibility testing of microbial biofilms
[J]. BMC Microbiol, 2005, 5: 53-64.

[10] Al-Fattani MA, Douglas LJ. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance
[J]. J Med Microbiol,2006, 55(Pt 8): 999-1008.

[11] De Prijck K, De Smet N, Coenye T, et al. Prevention of Candida albicans biofilm formation by covalently bound dimethylaminoethylmethacrylate and polyethylenimine
[J]. Mycopathologia,2010, 170(4): 213-221.

[12] Nailis H, Vandenbroucke R, Tilleman K, et al. Monitoring ALS1 and ALS3 gene expression during in vitro Candida albicans biofilm formation under continuous flow conditions
[J]. Mycopathologia, 2009, 167(1): 9-17.

[13] Frade JP, Arthington-Skaggs BA. Effect of serum and surface characteristics on Candida albicans biofilm formation
[J]. Mycoses,2011, 54(4): e154-e162.

[14] Li F, Svarovsky MJ, Karlsson AJ,et al. Eap1p, an adhesin that mediates Candida albicans biofilm formation in vitro and in vivo
[J]. Eukaryot Cell,2007, 6(6): 931-939.

[15] Samaranayake YH, Ye J, Yau JY, et al.In vitro method to study antifungal perfusion in Candida biofilms
[J]. J Clin Microbiol, 2005, 43(2): 818-825.

[16] Imamura Y, Chandra J, Mukherjee PK, et al. Fusarium and Candida albicans biofilms on soft contact lenses: model development, influence of lens type, and susceptibility to lens care solutions
[J]. Antimicrob Agents Chemother,2008, 52(1): 171-182.

[17] Chandra J, Mukherjee P K, Ghannoum M A.In vitro growth and analysis of Candida biofilms. Nature Protocols,2008, 3: 1909-1924.

[18] Nett J, Lincoln L, Marchillo K,et al. Beta-1,3 glucan as a test for central venous catheter biofilm infection
[J]. J Infect Dis,2007, 195(11): 1705-1712.

[19] Toulet D, Debarre C, Imbert C. Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials?
[J]. J Antimicrob Chemother,2012, 67(2): 430-432.

[20] Cateau E, Berjeaud JM, Imbert C. Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone
[J]. Int J Antimicrob Agents,2011, 37(4): 380-384.

[21] Richard ML, Nobile CJ, Bruno VM, et al.Candida albicans biofilm-defective mutants. Eukaryot Cell,2005, 4(8): 1493-1502.

[22] Negri M, Martins M, Henriques M, et al. Examination of Potential Virulence Factors of Candida tropicalis Clinical Isolates From Hospitalized Patients
[J]. Mycopathologia,2010, 169(3): 175-182.

[23] Dongari-Bagtzoglou A, Kashleva H, Dwivedi P, et al. Characterization of mucosal Candida albicans biofilms
[J]. PLoS ONE,2009, 4(11): e7967.

[24] Nett JE, Marchillo K, Spiegel CA, et al. Development and validation of an in vivo Candida albicans biofilm denture model
[J]. Infect Immun,2010, 78(9): 3650-3659.

[25] Paiva LCF, Vidigal PG, Donatti L, et al. Assessment of in vitro biofilm formation by Candida species isolates from vulvovaginal candidiasis and ultrastructural characteristics
[J]. Micron,2012, 43(2-3): 497-502.

[26] Harriott MM, Lilly EA, Rodriguez TE, et al.Candida albicans forms biofilms on the vaginal mucosa
[J]. Microbiology,2010, 156(Pt 12):3635-3644.

[27] Soňa Kucharíková, Hélène Tournu, Michelle Holtappels,et al.In vivo Efficacy of Anidulafungin against Mature Candida albicans Biofilms in a Novel Rat Model of Catheter-Associated Candidiasis
[J]. Antimicrob Agents Chemother,2010, 54(10): 4474-4475.

[28] Markéta Ricicová, Soňa Kucharíková, Hélène Tournu, et al.Candida albicans biofilm formation in a new in vivo rat model
[J]. Microbiology, 2010, 156(3): 909-919.

[29] 阳隽,张天托,朱家馨. 呼吸道白念珠菌分离株表型差异的机制
[J]. 南方医科大学学报,2012, 32(9): 1307-1311.

白念珠菌生物膜体内外模型研究进展

Advances of Candida albicans biofilm construction in vitro and in vivo

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘丹, 邢丽枝, 杨心茹, 罗伟, 何荣霞. 唑类药物治疗外阴阴道假丝酵母菌病研究进展[J]. 中国真菌学杂志, 2020, 15(5): 318-320.
[2]	马玉帛, 张逸, 黄晨, 王晓雯, 李若瑜. 自然杀伤细胞在真菌感染免疫的研究进展[J]. 中国真菌学杂志, 2020, 15(3): 175-178.
[3]	邱熙然, 陈思敏, 侯炜彤, 张玉, 郭诗雨, 姜远英, 安毛毛. 白念珠菌侵袭宿主毒力因子研究进展[J]. 中国真菌学杂志, 2020, 15(3): 183-188.
[4]	张静云, 彭靖雯, 王琼, 高盈, 陈万鑫, 沈永年, Li Dong-mei, 佘晓东, 刘维达. 表皮生长因子受体在阴道念珠菌病发病过程中的作用初探[J]. 中国真菌学杂志, 2020, 15(2): 65-71.
[5]	刘光荣, 翟春涛, 金敏蓉, 李成亮. 天然抗菌剂对5种致病菌的抑制作用研究[J]. 中国真菌学杂志, 2020, 15(2): 88-92.
[6]	谭静文, 徐红, 宋金凤, 高志琴, 杨虹, 杨连娟, 温海. 聚六亚甲基双胍体外抗真菌作用研究[J]. 中国真菌学杂志, 2020, 15(2): 93-96.
[7]	马生妍, 周学章. 氟尼辛葡甲胺对克柔念珠菌生物膜形成的影响及联合唑类药物效果评价[J]. 中国真菌学杂志, 2020, 15(1): 31-36.
[8]	张静云, 佘晓东, 刘维达. 白念珠菌糖代谢与毒力[J]. 中国真菌学杂志, 2020, 15(1): 61-64.
[9]	赵晓琴, 冯文莉. 转录因子在白念珠菌生物膜形成过程中的调控机制[J]. 中国真菌学杂志, 2019, 14(6): 381-384.
[10]	王钰婷, 王玉柱, 刘锦燕, 孟玲宁, 李卫华, 项明洁. 酵母相和菌丝相白念珠菌感染阴道上皮细胞免疫反应的比较[J]. 中国真菌学杂志, 2019, 14(4): 193-199.
[11]	蔡晴, 杨连娟, 高志琴, 任弘瑾, 杨虹, 谭静文. 罗米地辛对氟康唑体外抗白念珠菌影响的研究[J]. 中国真菌学杂志, 2019, 14(4): 200-203,216.
[12]	葛力瑜, 梁官钊, 刘维达. 抗黏膜白念珠菌感染的固有免疫研究进展[J]. 中国真菌学杂志, 2019, 14(4): 249-252.
[13]	姬名硕, 王晓东, 帕丽达·阿布利孜. NLRP3炎症小体在真菌感染中的作用机制研究进展[J]. 中国真菌学杂志, 2019, 14(4): 253-256.
[14]	施高翔, 姜晶晶, 汪云霞, 赵婷, 邵菁, 汪天明, 汪长中. 苦参-蛇床子药对提取物对白念珠菌VVC临床株的抑制作用研究[J]. 中国真菌学杂志, 2019, 14(3): 147-153.
[15]	沈煜宸, 曹毅, 陶茂灿. 白念珠菌生物膜耐药机制及中药治疗的研究进展[J]. 中国真菌学杂志, 2019, 14(3): 176-179.